Business
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to dateInitiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expected in Q3 2025, with topline data from both 4FRONT-1 and 4FRONT-2 expected in H2 2027RMAT designation received from FDA for 4D-150 in DME, adding to previous regulatory designations of RMAT and PRIME (EMA) for 4D-150 in wet AMD$458 million in cash, cash equivalents, and marketable securities as of Ma
About this update from 4d Molecular Therapeutics, Inc.
[{"type":"image","alt":"4D Molecular Therapeutics, Inc.","displaySize":"","headline":null,"caption":"4D Molecular Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/77c43650e1f3f7dcc5fea422c8ad89a8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OBgOYDeK6BG2g1ABskfhkQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/77c43650e1f3f7dcc5fea422c8ad89a8","width":300,"height":85}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to date","length":132,"tagName":"p"}]},{"val":[{"type":"text","content":"Initiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expected in Q3 2025, with topline data from both 4FRONT-1 and 4FRONT-2 expected in H2 2027","length":152,"tagName":"p"}]},{"val":[{"type":"text","content":"RMAT designation received from FDA for 4D-150 in DME, adding to previous regulatory designations of RMAT and PRIME (EMA) for 4D-150 in wet AMD","length":142,"tagName":"p"}]},{"val":[{"type":"text","content":"$458 million in cash, cash equivalents, and marketable securities as of March 31, 2025, expected to fund planned operations into 2028","length":133,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":559,"olType":false},{"type":"text","content":"EMERYVILLE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q1 2025 financial results, provided operational highlights and outlined expected upcoming milestones.","length":423,"tagName":"p"},{"type":"text","content":"“The first quarter of 2025 marked a pivotal moment for 4DMT as we focused our pipeline on our highest value programs, 4D-150 and 4D-710, reported compelling 4D-150 Phase 2 results in wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), and initiated our first 4D-150 Phase 3 clinical trial 4FRONT-1 in wet AMD,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. “With strong Pha...